China Biologic Products (CBPO) : The total negative money flow of $1.63 million on Wednesday indicates selling on strength. The inflow of money on upticks was $2.74 million, compared to $4.37 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.63. The negative money flow of $0 million in block trades reveals that the informed traders sold the stock on every bit of price strength.The transaction value of block trade on downtick was $0 million. The price action in the China Biologic Products (CBPO) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $124.16 with a gain of $2.02 , a change of 1.65% over the previous days close. The stock registered -1.53% for the week.
Shares of China Biologic Products, Inc. rose by 1.55% in the last five trading days and 12.13% for the last 4 weeks. China Biologic Products, Inc. is up 18.84% in the last 3-month period. Year-to-Date the stock performance stands at -11.79%.
China Biologic Products (CBPO) has an average broker rating of 1, which is interpreted as a Strong Buy, as rated by 3 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
China Biologic Products (NASDAQ:CBPO): The stock opened at $122.88 and touched an intraday high of $125.88 on Wednesday. During the day, the stock corrected to an intraday low of $122.2, however, the bulls stepped in and pushed the price higher to close in the green at $125.67 with a gain of 2.89% for the day. The total traded volume for the day was 205,528. The stock had closed at $122.14 in the previous trading session.
China Biologic Products, Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Companys principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries, namely, Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also holds an interest in Xian Huitian Blood Products Co., Ltd., a plasma products company. Its products include human albumin, human immunoglobulin, IVIG, thymopolypeptides injection, human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).